Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Soft Tissue Sarcoma
Interventions
COMBINATION_PRODUCT

SBRT + MEDI5752

"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"

Trial Locations (5)

Unknown

Institut Bergonié, Bordeaux

Centre Oscar Lambret, Lille

Centre Leon Berard, Lyon

Institut Regional Du Cancer de Montpellier, Montpellier

IUCT-O, Toulouse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

AstraZeneca

INDUSTRY

lead

Institut Claudius Regaud

OTHER